6.07
                                            Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - WV News
Karyopharm (KPTI) Reports Strong Q3 2025, Highlights Myelofibros - GuruFocus
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year 2025 - MarketScreener
Transcript : Karyopharm Therapeutics Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Karyopharm Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Karyopharm Therapeutics: Q3 Earnings Snapshot - CTPost
Karyopharm Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Earnings call transcript: Karyopharm Q3 2025 shows revenue growth, pre-market dip - Investing.com
How geopolitical tensions affect Karyopharm Therapeutics Inc. stock2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com
Karyopharm Grows Revenue With Strong XPOVIO Sales And Partnerships - Finimize
Is Karyopharm Therapeutics Inc. (25K0) stock a top hedge fund pickIPO Watch & Safe Capital Growth Trade Ideas - newser.com
Analyzing net buyer seller activity in Karyopharm Therapeutics Inc.July 2025 Final Week & High Accuracy Trade Signal Alerts - newser.com
Karyopharm (KPTI) Surpasses Q3 Revenue Expectations with Clinica - GuruFocus
Karyopharm (KPTI) Projects Revenue Growth and Expense Reduction for FY25 - GuruFocus
Karyopharm Therapeutics Inc. SEC 10-Q Report - TradingView
Karyopharm Therapeutics' Q3 net loss widens - TradingView
Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress - PR Newswire
How Karyopharm Therapeutics Inc. (25K0) stock reacts to new regulationsQuarterly Market Review & Verified Technical Trade Signals - newser.com
Quantitative breakdown of Karyopharm Therapeutics Inc. recent moveWeekly Trade Recap & Daily Risk Controlled Trade Plans - newser.com
Karyopharm Therapeutics Inc. stock trend outlook and recovery path2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - newser.com
Is it time to cut losses on Karyopharm Therapeutics Inc.July 2025 EndofMonth & Weekly Setup with High ROI Potential - newser.com
Using Ichimoku Cloud for Karyopharm Therapeutics Inc. technicalsQuarterly Earnings Report & Free Fast Gain Swing Trade Alerts - newser.com
Is Karyopharm Therapeutics Inc. (25K0) stock cheap vs fundamentalsMarket Performance Summary & Fast Entry High Yield Stock Tips - newser.com
Will Karyopharm Therapeutics Inc. stock benefit from AI adoptionJuly 2025 Drop Watch & Growth Focused Stock Reports - newser.com
Can Karyopharm Therapeutics Inc. stock continue upward trend2025 Market Sentiment & Daily Stock Trend Reports - newser.com
What makes Karyopharm Therapeutics Inc. (25K0) stock appealing to growth investors2025 Technical Overview & Reliable Volume Spike Alerts - newser.com
Is Karyopharm Therapeutics Inc. stock safe for conservative investorsPortfolio Profit Report & AI Based Buy/Sell Signal Reports - newser.com
Is Karyopharm Therapeutics Inc. stock vulnerable to regulatory risksWeekly Earnings Recap & Weekly Return Optimization Alerts - newser.com
Karyopharm Therapeutics Inc expected to post a loss of $3.13 a shareEarnings Preview - TradingView
Earnings To Watch: Karyopharm Therapeutics Inc (KPTI) Reports Q3 2025 Result - Yahoo Finance
Technical signs of recovery in Karyopharm Therapeutics Inc.2025 Technical Overview & Safe Entry Trade Signal Reports - newser.com
Regression analysis insights on Karyopharm Therapeutics Inc. performance2025 Year in Review & Free High Accuracy Swing Entry Alerts - newser.com
Published on: 2025-10-31 05:27:00 - newser.com
Can Karyopharm Therapeutics Inc. (25K0) stock sustain revenue momentumQuarterly Performance Summary & Daily Chart Pattern Signals - newser.com
Karyopharm Therapeutics (KPTI) Price Target Decreased by 10.98% to 15.98 - MSN
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Above 50-Day Moving AverageHere's What Happened - MarketBeat
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):